日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial

Nirsevimab在日本婴儿中的安全性和药代动力学:开放标签JUBILUS试验的主要分析

Mori, Masaaki; Leach, Susannah; Learoyd, Maria; Vijapur, Divya; Sadow, Sam; Wilkins, Deidre; Abe, Yoshifusa; Ikeda, Kazushige; Kanegane, Hirokazu; Kano, Zempei; Moriuchi, Hiroyuki; Muneuchi, Jun; Nishikomori, Ryuta; Okazaki, Kaoru; Takas, Therese; Sakaguchi, Ayako; Villafana, Tonya

A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

基于SARS-CoV-2变异株调整的单克隆抗体暴露前预防COVID-19的保护阈值模型

Edge, Rhiannon; Matthews, Sam; Ahani, Bahar; Aksyuk, Anastasia A; Clegg, Lindsay; Perez, John L; Esser, Mark T; Chang, Lee-Jah; Hirsch, Ian; Villafana, Tonya; Pura, John; Stepanov, Oleg; Streicher, Katie; White, Tom; Cohen, Taylor S; Follmann, Dean; Gilbert, Peter B; Seegobin, Seth

Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)

呼吸道合胞病毒单克隆抗体Nirsevimab免疫接种与安慰剂治疗下呼吸道感染的疗效比较:一项3期随机临床试验(MELODY)的分析

Arbetter, Doug; Gopalakrishnan, Vancheswaran; Aksyuk, Anastasia A; Ahani, Bahar; Chang, Yue; Dagan, Ron; Esser, Mark T; Hammitt, Laura L; Mankad, Vaishali S; Saez-Llorens, Xavier; Shen, David; Leach, Amanda; Kelly, Elizabeth J; Villafana, Tonya; Wilkins, Deidre

Promoter Frame Position Affects Strength and Nature of Circadian Oscillations in hPER2 Luciferase Reporters

启动子框架位置影响hPER2荧光素酶报告基因昼夜节律振荡的强度和性质

Kalyanaraman, Bhavna; Villafana, Gabrielle; Taylor, Stephanie R; Farkas, Michelle E

Colistin-Resistant Escherichia coli Isolated from Houseflies and Feces of Cattle and Pigs at a Slaughterhouse in Lima, Peru

从秘鲁利马一家屠宰场的家蝇以及牛猪粪便中分离出耐粘菌素大肠杆菌

Carhuallanqui, Andrea; Villafana, Lorena; Gonzalez-Veliz, Rosa; Cobo-Díaz, José F; Álvarez-Ordoñez, Avelino; Ramos-Delgado, Daphne Doris

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

一项 I 期随机、安慰剂对照试验,旨在评估 nirsevimab 在健康中国成年人中的药代动力学、安全性和耐受性。

Mao, Xiaomeng; Hua, Xiaohan; Wu, Chengyi; Ge, Xiaoyun; Zhang, Jie; Wu, Xiaojie; Kubiak, Robert J; Wählby Hamrén, Ulrika; Villafana, Tonya; Christou, Georgios; Green, Jannine; Takas, Therese; Jin, Yuwen

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

ChAdOx1 nCoV-19 (AZD1222) 作为同源第四剂加强针的免疫原性和安全性:巴西 3 期 COV003 试验的子研究

Costa Clemens, Sue Ann; Bibi, Sagida; Marchevsky, Natalie G; Aley, Parvinder K; Cappuccini, Federica; Davies, Sophie A; Gonzalez, Isabela; Kelly, Sarah C; Mujadidi, Yama F; Pipolo Milan, Eveline; Schwarzbold, Alexandre V; Sprinz, Eduardo; Voysey, Merryn; Weckx, Lily Y; Wright, Daniel; Bansal, Himanshu; Bergagård, Maria A S; Isaacs, Abby J; Kelly, Elizabeth J; Lan, Dongmei; Morgan, Shethah; Shankar, Nirmal Kumar; Shoemaker, Kathryn; Villafana, Tonya L; Lambe, Teresa; Green, Justin A; Pollard, Andrew J

Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

作者更正:尼塞维单抗给药后中和性RSV抗体的持久性以及婴儿对RSV感染的自然免疫反应的诱导

Wilkins, Deidre; Yuan, Yuan; Chang, Yue; Aksyuk, Anastasia A; Núñez, Beatriz Seoane; Wählby-Hamrén, Ulrika; Zhang, Tianhui; Abram, Michael E; Leach, Amanda; Villafana, Tonya; Esser, Mark T

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

AZD1222 (ChAdOx1 nCoV-19) 的长期安全性和免疫原性:一项 3 期研究的 2 年随访结果

Shoemaker, Kathryn; Soboleva, Karina; Branche, Angela; Shankaran, Shivanjali; Theodore, Deborah A; Bari, Muhammad; Ezeh, Victor; Green, Justin; Kelly, Elizabeth; Lan, Dongmei; Olsson, Urban; Saminathan, Senthilkumar; Shankar, Nirmal Kumar; Villegas, Berta; Villafana, Tonya; Falsey, Ann R; Sobieszczyk, Magdalena E

Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

接受单剂尼塞维单抗预防呼吸道合胞病毒感染的婴儿,在第二个呼吸道合胞病毒感染季中未出现病情加重的迹象。

Dagan, Ron; Hammitt, Laura L; Seoane Nuñez, Beatriz; Baca Cots, Manuel; Bosheva, Miroslava; Madhi, Shabir A; Muller, William J; Zar, Heather J; Chang, Yue; Currie, Alexander; Grenham, Amy; Shroff, Manish; Takas, Therese; Mankad, Vaishali S; Leach, Amanda; Villafana, Tonya